← Back to Search

Procedure

Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma

Phase 2 & 3
Waitlist Available
Led By Michel Kahaleh, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
No Placebo-Only Group

Summary

Successful palliation of biliary obstruction is the main goal for reducing morbidity and mortality in patients with biliary disease and biliary obstruction related to cholangiocarcinoma. Surgical intervention for the sale is unfortunately complicated by a 30-day postoperative mortality rate of between 7 and 24%. Moreover, because of recovery time the quality of life following surgery is only improved in a minority. At present endoscopic insertion of a plastic or metal stent is the method of choice to relieve obstructive jaundice without the high morbidity and mortality associated with surgery. But this relief is unfortunately temporary since stents tend to become obstructed and the fact that effective biliary drainage in the proximal lesion is challenging. Photodynamic Therapy (PDT) is a new therapeutic approach that specifically targets neoplastic cells. This therapy involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. A randomized controlled trial study by Ortner et all confirmed the significant advantage of PDT with regard to relief of jaundice, quality of life, and survival. In photodynamic therapy (PDT) the uniform distribution of externally applied light is desirable but often difficult to achieve. An optical fiber tip producing cylindrical or lateral light emission can facilitate the application of laser energy by direct implantation of the tip into solid tumors. However, currently used FDA approved glass diffusers used in standard of care PDT might break in the bile ducts causing injury since they are not meant to be used within bile ducts through an endoscope or choledochoscope. Hence, there is a need to evaluate and introduce more efficient and safe non-glass cylindrical optic fiber diffuser for photo dynamic therapy in the bile ducts. Recent studies have shown that the Pioneer plastic optic diffuser is safe and effective in photodynamic therapy, it can be also used via a choledochoscope. We aim to add to the clinical evidence by conducting an open label observational study trial using this fiber optic diffuser during photo dynamic therapy in the bile ducts.

Eligible Conditions
  • Cholangiocarcinoma
  • Biliary Strictures
  • Biliary Obstruction
  • Bile Duct Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy Profile
Secondary study objectives
Safety Profile

Side effects data

From 2012 Phase 2 trial • 73 Patients • NCT00217087
32%
Photosensitivity
16%
Dysphagia
5%
heart attack resulting in death
3%
Dehydration
3%
Respitory Failure / Sepsis
3%
Bleeding
3%
Pain
3%
Renal failure - Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Photodynamic Therapy
Endoscopic Mucosl Resection

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PDT GroupExperimental Treatment1 Intervention
Subjects who receive Photodynamic therapy with plastic optic diffuser.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Photodynamic Therapy
2014
Completed Phase 4
~460

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,091 Previous Clinical Trials
1,154,690 Total Patients Enrolled
9 Trials studying Cholangiocarcinoma
13,495 Patients Enrolled for Cholangiocarcinoma
Michel Kahaleh, MDPrincipal InvestigatorWeill Medical College of Cornell University
13 Previous Clinical Trials
24,388 Total Patients Enrolled
7 Trials studying Cholangiocarcinoma
13,318 Patients Enrolled for Cholangiocarcinoma
~4 spots leftby Dec 2025